PD38-12 LONG-TERM PATIENT-REPORTED OUTCOMES OF VIBEGRON FOR OVERACTIVE BLADDER: ANALYSES FROM THE EMPOWUR EXTENSION TRIAL

Abstract

You have accessJournal of UrologyCME1 May 2022PD38-12 LONG-TERM PATIENT-REPORTED OUTCOMES OF VIBEGRON FOR OVERACTIVE BLADDER: ANALYSES FROM THE EMPOWUR EXTENSION TRIAL David Staskin, Susann Varano, Heather Greene, Elizabeth Thomas, and Jeffrey Frankel David StaskinDavid Staskin More articles by this author , Susann VaranoSusann Varano More articles by this author , Heather GreeneHeather Greene More articles by this author , Elizabeth ThomasElizabeth Thomas More articles by this author , and Jeffrey FrankelJeffrey Frankel More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002596.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Overactive bladder (OAB) may significantly impact quality of life (QoL) if not managed well. Vibegron is efficacious for OAB, shown in the 12-week phase 3 EMPOWUR trial and in the 40-week EMPOWUR extension trial. Vibegron showed significantly greater improvements vs placebo at week 12 in OAB questionnaire (OAB-q) scores and Patient Global Impression (PGI) scores, 2 patient-reported outcome (PRO) tools concerning QoL. This analysis of the EMPOWUR extension trial investigated the long-term effect of vibegron on QoL. METHODS: Patients completing EMPOWUR could enter the 40-week extension (NCT03583372) and continue vibegron 75 mg or tolterodine 4 mg extended release or be randomly assigned treatment 1:1 (if previously on placebo). The OAB-q (health-related QoL [HRQL] total [comprising coping, concern, sleep, social interaction] and symptom bother) and PGI items (Severity, Control, Frequency, Leakage, Change) were completed at baseline and at weeks 12, 24, and 52. Descriptive statistics were used to analyze change from baseline at week 52 in OAB-q HRQL total and subscale scores and PGI subscale scores among patients receiving 52 weeks of active treatment. RESULTS: Overall, 298 patients (n=164, vibegron; n=134, tolterodine) and 300 patients (n=166, vibegron; n=134, tolterodine) had evaluable change from baseline at week 52 OAB-q and PGI scores, respectively. Baseline PRO scores were similar between treatment groups. Improvements in OAB-q scores seen in the 12-week trial were maintained for the 40-week extension for patients continuing on vibegron for 52 weeks (Table). Improvements from baseline in the PGI subscale scores from the 12-week trial were also maintained with continuing treatment in the 40-week extension; at week 52, 69.9% of patients receiving vibegron experienced ≥1-category improvement in PGI-Severity; 69.9%, PGI-Control; 74.4%, PGI-Frequency; 74.8%, PGI-Leakage; and 67.6%, PGI-Change (Table). CONCLUSIONS: Consistent with long-term improvements in OAB symptoms and a favorable safety and tolerability profile, vibegron for 52 weeks was associated with sustained and patient-perceived meaningful improvements in OAB-q and PGI scores in the EMPOWUR extension trial. Source of Funding: Urovant Sciences © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e650 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information David Staskin More articles by this author Susann Varano More articles by this author Heather Greene More articles by this author Elizabeth Thomas More articles by this author Jeffrey Frankel More articles by this author Expand All Advertisement PDF DownloadLoading ...